Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 749

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 749
---
 although it is probable that it will be more efficient when given to patients that are in the early stages of the illness. The total available market therefore comprises every case of ALS. We have assumed that the relevant markets for the Company in the first years of sales are as follows: U.S.A, Japan and the five largest European economies (Germany, UK, France, Italy and Spain). In the following table we present the ALS prevalence in these markets:

| Country    |     |  Population |     | Prevalence 
   per 100k |     | Prevalence |
| USA        |     | 345,426,571 |     |       8.63 |     |     29,824 |
| EU_Germany |     |  84,552,242 |     |       6.23 |     |      5,268 |
| EU_France  |     |  66,548,530 |     |       6.23 |     |      4,146 |
| EU_U.K     |     |  69,138,192 |     |       4.03 |     |      2,786 |
| EU_Spain   |     |  47,910,526 |     |       6.89 |     |      3,301 |
| EU_Italy   |     |  59,342,867 |     |       7.85 |     |      4,658 |
| Japan      |     | 123,753,041 |     |       7.96 |     |      9,851 |
| Total      |     | 796,671,969 |     |       7.51 |     |     59,834 |
| Total EU   |     | 327,492,357 |     |       6.16 |     |     20,159 |

IsletRx According to the company, the IsletRx is developed for the treatment of Insulin Dependent Diabetes, meaning that the total available market for this indication is comprised of 100% of type 1 Diabetes cases and 30% of type 2 Diabetes cases. In the following table we present the total available market for IsletRx in the U.S.A, Japan and the 5 largest European economies:

| Country    |     |  Population |     | Ages 20 – 79 
  Types 1 & 2 |     | Ages 0 –